Login / Signup

CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease.

Jennifer S MichaelsonPatrick A Baeuerle
Published in: The Journal of experimental medicine (2024)
Jennifer S. Michaelson, Chief Scientific Officer at Cullinan Oncology, and Patrick A. Baeuerle, scientific advisor to Cullinan Oncology and honorary professor in immunology at Ludwig Maximilians University Munich, discuss the use of CD19-specific T cell-engaging antibody therapies (TCEs) as therapeutics for autoimmune diseases.
Keyphrases
  • palliative care
  • nk cells
  • multiple sclerosis
  • small molecule
  • combination therapy
  • drug induced
  • smoking cessation